Trial record 1 of 1 for:    PREADVISE
Previous Study | Return to List | Next Study

Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00040378
Recruitment Status : Completed
First Posted : June 27, 2002
Last Update Posted : March 14, 2018
National Institute on Aging (NIA)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Frederick Schmitt, University of Kentucky

Brief Summary:
The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Condition or disease Intervention/treatment
Alzheimer Disease Drug: alphatocopherol Drug: Selenium Drug: Placebo replacement for vitamin E Drug: Placebo replacement for Selenium

Detailed Description:

Studies show that increased oxidative stress (from excess free radicals) may damage brain cells and is linked with Alzheimer's disease (AD). Many studies show increased oxidation of brain lipids (fats), proteins, carbohydrates (sugars) and DNA in AD. Although the causes of AD are not known, it is believed that oxidative stress is part of what damages brain cells in AD and probably other brain diseases. Animal and tissue culture studies of vitamin E and selenium suggest that they can protect brain cells from damage. This research study is being done to see how safe and effective vitamin E and selenium may be in preventing AD and other brain illnesses. These illnesses are more common in people over the age of 60 to 65. A potential benefit of participating in the PREADVISE study is that early detection of memory changes can lead to early diagnosis and treatment. Also, some participants may decrease their risk of getting AD if the supplements are effective. The findings of this study may also help in the research and understanding of AD.

Only participants who are taking part in the SELECT study (a study that looks at the use of vitamin E and selenium for preventing prostate cancer) may apply to participate in the PREADVISE study about how useful vitamin E and selenium might be for preventing memory changes with age (including Alzheimer's disease and other disease that can affect the brain). African American and Hispanic men who are age 60 or older may take part. Men of other ethnic groups aged 62 or older may take part. The SELECT doctors or staff will review the applicant's medical history and drugs to verify that they have no conditions that would exclude them from this study. About 10,000 men will take part in this study.

The PREADVISE study examinations will be done during the participant's annual SELECT visit at the clinic where the SELECT studies are being conducted. There will be one study visit for each year the participants are in SELECT (7 to 12 visits). Each visit for PREADVISE will consist of a brief screening of the participant's memory, and an update (if any) of the participant's family history of dementia and medications. If memory changes are suggested by the brief memory screen, the participant will be asked to take a longer memory screen to further evaluate the potential for memory changes. If the longer memory screen also suggests problems with the participant's memory, the participant will be asked to see his family doctor or a PREADVISE doctor for a more complete medical exam to find the possible causes of the memory change. Results of the doctor's medical exam, with the consent of the participant, will be sent to the PREADVISE doctors for their review to help with the diagnosis. Results of the memory checks will not be given to the participants. However, if the participant does have a medical workup for memory changes, this information will be given to the family doctor after the medical workup is completed. A portion of the blood sample that was taken when the participant entered SELECT might be analyzed and tested for a genetic risk factor associated with Alzheimer's disease, called Apolipoprotein E (ApoE). The results of this test will be used for research purposes only.

Study Type : Observational
Actual Enrollment : 4246 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)
Actual Study Start Date : May 2002
Actual Primary Completion Date : January 2014
Actual Study Completion Date : August 2016

Group/Cohort Intervention/treatment
Combination therapy
vitamin E (alphatocopherol) and selenium
Drug: alphatocopherol
400 IU daily
Other Name: Vitamin E

Drug: Selenium
200mcg daily

Vitamin E only
vitamine E (alphatocopherol) and placebo
Drug: alphatocopherol
400 IU daily
Other Name: Vitamin E

Drug: Placebo replacement for Selenium
1 placebo pill daily

Selenium only
selenium and placebo (Placebo replacement for vitamin E)
Drug: Selenium
200mcg daily

Drug: Placebo replacement for vitamin E
1 placebo pill daily

placebo (Placebo replacement for vitamin E) and placebo (Placebo replacement for selenium)
Drug: Placebo replacement for vitamin E
1 placebo pill daily

Drug: Placebo replacement for Selenium
1 placebo pill daily

Primary Outcome Measures :
  1. incidence of dementia (including Alzheimer's disease) [ Time Frame: 7 to 12 years (depending on enrollment date) ]
    Participants will complete a modified Telephone Interview of Cognitive Status (TIC-S) to evaluate the onset of dementia

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   60 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Participant will be recruited from primary care office visits

Inclusion Criteria:

  • Participating in SELECT Prevention study;
  • 62 years or older if other ethnic origin, or 60 years or older if African-American or Hispanic;
  • General good health with no neurological or psychiatric illness.

Exclusion Criteria:

The SELECT doctors or staff will review the PREADVISE applicants' medical history and drugs to verify that they have no condition(s) that would exclude them from this study. The participant must not have any of the following neurological conditions based on self report (were told by a physician):

  • Alzheimer's disease, or any other form of dementia such as Pick's disease, dementia with Lewy bodies, frontotemporal dementia, vascular dementia, significant cognitive and motor impairment from a stroke or corticobasal degeneration;
  • Huntington's disease, epilepsy, Parkinson's disease, brain tumor, multiple sclerosis, manic-depressive disorder, or schizophrenia;
  • The participant must not have had a head injury with prolonged loss of consciousness (over 30 minutes) within the past five years;
  • The participant must not have a current alcohol or substance abuse diagnosis, or must have been treatment free for the past 24 months;
  • The participant must not have had a diagnosis of depression or anxiety disorder in the past 4 months and must not currently be under treatment for depression or anxiety disorder. [A participant who was previously diagnosed with depression or anxiety disorder but completed treatment more than four months ago is eligible.];
  • The participant must not currently use of any of the following medications: Aricept, Cognex, Exelon, Reminyl, or Hydergine;
  • The participant must not have blindness, deafness, language difficulties or any other disability that may prevent completion of the memory screen.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00040378

  Hide Study Locations
United States, Alabama
University of Alabama at Birmingham Preventive Medicine
Birmingham, Alabama, United States, 35294-4410
United States, Alaska
Alaska Regional Hospital
Anchorage, Alaska, United States, 99508
Providence Alaska Medical Center
Anchorage, Alaska, United States, 99508
United States, California
University of California, San Diego - Chula Vista
Chula Vista, California, United States, 91910
Glendale Memorial Hospital
Glendale, California, United States, 91204
University of California, San Diego
La Jolla, California, United States, 92037-1709
VA Medical Center
Loma Linda, California, United States, 92354-3866
VAMC Long Beach
Long Beach, California, United States, 90822
Northridge Hospital Medical Center
Northridge, California, United States, 91328
Santa Rosa Memorial Hospital Regional CCOP
Santa Rosa, California, United States, 95403
LABIOMED (Los Angeles Biomedical) Research Institute at Harbor-UCLA Medical Center
Torrance, California, United States, 90502-2064
Lionel B. Katchem
Upland, California, United States, 91786
United States, Colorado
Rocky Mountain CC/Poudre Valley Hospital
Fort Collins, Colorado, United States, 80524
United States, District of Columbia
Sibley Memorial Hospital
Washington, District of Columbia, United States, 20016
George Washington University Medical Center
Washington, District of Columbia, United States, 20037
Washington, District of Columbia, United States, 20060-0001
United States, Florida
Baptist Medical Center
Jacksonville, Florida, United States, 32207-8560
United States, Georgia
Kaiser Southeast Permanente Medical Group
Tucker, Georgia, United States, 30084
United States, Iowa
Bliss Cancer Center/McFarland Clinic/Mary Greely MC
Ames, Iowa, United States, 50010
Cedar Rapids CCOP
Cedar Rapids, Iowa, United States, 52403
Genesis Medical Center
Davenport, Iowa, United States, 52804
Iowa Oncology Research Association
Des Moines, Iowa, United States, 50309-1016
Siouxland Hematology-Oncology Associates
Sioux City, Iowa, United States, 51101
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
Stormont-Vail Health Care/Cotton O'Neil Clinic
Topeka, Kansas, United States, 66606
Wichita CCOP
Wichita, Kansas, United States, 67214-3882
United States, Kentucky
Our Lady of Bellefonte Hospital Inc.
Ashland, Kentucky, United States, 41101
University of Kentucky Medical Center
Lexington, Kentucky, United States, 40536-0093
Louisville VA Medical Center
Louisville, Kentucky, United States, 40206-1499
United States, Maryland
Anne Arundel Medical Center
Annapolis, Maryland, United States, 21401-2777
United States, Massachusetts
Berkshire Hematology Oncology/Bershire Medical Center
Pittsfield, Massachusetts, United States, 01201
United States, Michigan
Bixby Oncology Center
Adrian, Michigan, United States, 49221
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Grand Rapids Clinical Oncology Program CCOP
Grand Rapids, Michigan, United States, 49503-2560
Monroe Clinic
Monroe, Michigan, United States, 48162
St. Joseph Mercy Oakland
Pontiac, Michigan, United States, 48341
Munson Medical Center
Traverse City, Michigan, United States, 49684-2386
United States, Minnesota
Duluth CCOP
Duluth, Minnesota, United States, 55805
United States, Missouri
St. John's Regional Medical Center
Joplin, Missouri, United States, 64804
St. John's Health System
Springfield, Missouri, United States, 65804
Cancer Research for the Ozarks
Springfield, Missouri, United States, 65807
United States, Montana
Montana Cancer Consortium CCOP
Billings, Montana, United States, 59101
Benefis Health Care
Great Falls, Montana, United States, 59405
United States, Nebraska
Good Samaritan Health Systems - Cancer Center
Kearney, Nebraska, United States, 68847
Cancer Resource Center
Lincoln, Nebraska, United States, 68510-4844
Alegent Health Immanuel Medical Center
Omaha, Nebraska, United States, 68122
Alegent Health Bergan Mercy Medical Center
Omaha, Nebraska, United States, 68124
Missouri Valley Cancer Cons CCOP/Creighton University
Omaha, Nebraska, United States, 68131
United States, Nevada
Washoe Medical Center
Reno, Nevada, United States, 89520
United States, New Jersey
VAMC New Jersey Health Care System
East Orange, New Jersey, United States, 07018-1095
Warren Hospital
Phillipsburg, New Jersey, United States, 08865
Riverview Medical Center
Red Bank, New Jersey, United States, 07701
United States, New York
Stratton Veterans Affairs Medical Center
Albany, New York, United States, 12208
Bassett Research Institute
Cooperstown, New York, United States, 13326-1394
Glens Falls Hospital
Glens Falls, New York, United States, 12801
United States, Ohio
Good Samaritan Hospital
Cincinnati, Ohio, United States, 45220-2489
Columbus CCOP
Columbus, Ohio, United States, 43206
Fremont Memorial Hospital
Fremont, Ohio, United States, 43420
NW Ohio Oncology Center/St. Luke's Hospital
Maumee, Ohio, United States, 43537
St. Charles Hospital
Oregon, Ohio, United States, 43616
Flower Hospital
Sylvania, Ohio, United States, 43560-2197
Toledo Hospital
Toledo, Ohio, United States, 43606
St. Vincent Medical Center
Toledo, Ohio, United States, 43608
Toledo CCOP
Toledo, Ohio, United States, 43623
Toledo Clinic Inc.
Toledo, Ohio, United States, 43623
United States, Oklahoma
Muskogee Regional Medical Center
Muskogee, Oklahoma, United States, 74401-5075
United States, Pennsylvania
Abington Memorial Hospital
Abington, Pennsylvania, United States, 19001-3788
Lehigh Valley Hospital
Allentown, Pennsylvania, United States, 18103
St. Luke's Hospital and Health Network
Bethlehem, Pennsylvania, United States, 18015
Doylestown Hospital
Doylestown, Pennsylvania, United States, 18901
York Cancer Center/Wellspan Health
York, Pennsylvania, United States, 17403-5049
United States, South Dakota
Sioux Community Cancer Consortium
Sioux Falls, South Dakota, United States, 57105
United States, Tennessee
Thompson Cancer Survival Center
Knoxville, Tennessee, United States, 37916
Baptist Memorial Hospital - Memphis
Memphis, Tennessee, United States, 38120
Meharry Medical College
Nashville, Tennessee, United States, 37208-3599
Methodist Regional Cancer Center
Oak Ridge, Tennessee, United States, 37830
United States, Texas
Methodist Hospitals of Dallas
Dallas, Texas, United States, 75203
Scott & White CCOP
Temple, Texas, United States, 76508
United States, Washington
Cascadia Clinical Trials at St. Joseph Hospital
Bellingham, Washington, United States, 98225-1898
Virginia Mason CCOP
Seattle, Washington, United States, 98101
Swedish Medical Center
Seattle, Washington, United States, 98104
Northwest Hospital
Seattle, Washington, United States, 98133
United States, Wisconsin
Marshfield Clinic
Marshfield, Wisconsin, United States, 54449-5703
Sinai Samaritan Medical Center
Milwaukee, Wisconsin, United States, 53233
Canada, Ontario
Ottawa General Hospital
Ottawa, Ontario, Canada, K1H 8L6
Puerto Rico
San Juan Dr. I. Gonzalez Martinez/Centro Medico
San Juan, Puerto Rico, 00919-1811
Altamira Family Medicine
San Juan, Puerto Rico, 00920
Centro Clinico San Patricio
San Juan, Puerto Rico, 00921
Miguel Sosa Padilla, MD/San Juan City Hospital
San Juan, Puerto Rico, 00926
VAMC San Juan
San Juan, Puerto Rico, 00927
San Juan City Hospital - PR, Hematology Oncology Office
San Juan, Puerto Rico, 00936-8344
Sponsors and Collaborators
Frederick Schmitt
National Institute on Aging (NIA)
National Cancer Institute (NCI)
Principal Investigator: Frederick Schmitt, PhD Sanders-Brown Center on Aging
Principal Investigator: Richard Kryscio, PhD Sanders-Brown Center on Aging

Additional Information:
Publications of Results:
Other Publications:

Responsible Party: Frederick Schmitt, Principal Investigator, University of Kentucky Identifier: NCT00040378     History of Changes
Obsolete Identifiers: NCT00780689
Other Study ID Numbers: IA0033
5R01AG019241 ( U.S. NIH Grant/Contract )
First Posted: June 27, 2002    Key Record Dates
Last Update Posted: March 14, 2018
Last Verified: March 2018

Keywords provided by Frederick Schmitt, University of Kentucky:
Alzheimer Disease
Vitamin E

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Vitamin E
Growth Substances
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Protective Agents
Trace Elements